Pfizer (NYSE:PFE) Trading 3.7% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE) shot up 3.7% during trading on Wednesday . The company traded as high as $28.44 and last traded at $28.2470. Approximately 59,373,284 shares changed hands during trading, an increase of 41% from the average daily volume of 42,257,406 shares. The stock had previously closed at $27.25.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported completion or initiation of several clinical studies, providing evidence of continued pipeline activity. Updates covered PF-07868489 for pulmonary arterial hypertension, atirmociclib in liver-related research, PF-07248144 drug-interaction testing, a prostate-cancer real-world study, and a Phase 4 migraine study in India. These are early-stage or evidence-gathering developments rather than efficacy announcements, but they support the long-term product-renewal narrative. PF-07868489 study Atirmociclib study
• Positive Sentiment: Analysts and income-focused investors remain constructive on Pfizer, citing its roughly 6.3% dividend yield, potential for patient investors to be rewarded, and reported hedge-fund buying in recent 13F filings. Pfizer’s strong year-to-date performance and proximity to a 52-week high may also be reinforcing momentum. Dividend and hedge-fund buying
• Neutral Sentiment: Pfizer completed a real-world Ibrance breast-cancer study. The result could help support market-positioning and treatment evidence, but the update disclosed no new clinical outcome or immediate financial impact. Ibrance study
• Negative Sentiment: Investors continue to weigh Pfizer’s exposure to patent expirations and the need for new products to replace declining legacy revenue. Analysts also flagged a settlement program involving thousands of Depo-Provera lawsuits, creating uncertainty around legal costs and financial exposure. Patents and new drugs Legal claims
• Negative Sentiment: Merck’s expanding personalized cancer-vaccine ambitions raise the competitive bar for Pfizer and BioNTech, potentially increasing development and commercialization pressure in a key growth market. Cancer-vaccine competition

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Guggenheim dropped their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. cut their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Price Performance

The firm has a market cap of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a 50-day simple moving average of $25.27 and a 200 day simple moving average of $26.24.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the firm posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the company. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer in the second quarter valued at approximately $26,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Field & Main Bank purchased a new position in Pfizer in the 2nd quarter valued at $27,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.